当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.

Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.

Abstract：

:IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the ER-mediated induction of progesterone receptor (PgR). ER level in IBEP-2 cells, determined by enzyme-linked immunoassay (EIA), was slightly higher than that measured in MCF-7 cells (662 v.s. 595 fmol/mg protein). When tested on IBEP-2 and MCF-7, various agonists stimulated cell growth with EC50's reflecting different estrogenic potencies (E(2) approximately diethylstilbestrol > E(1) > genistein). IBEP-2 appeared slightly more sensitive than MCF-7, especially to E(2) (at least 4-fold difference between EC50 values). By contrast, IBEP-2 and MCF-7 were equally sensitive to the growth inhibitory effect of antiestrogens 4-hydroxy-tamoxifen (OH-Tam) and ICI 182,780. As revealed by immunoblotting and immunofluorescence using anti-ER alpha antibodies, ER expression in IBEP-2 cells was modulated by E(2) and estrogen antagonists like it has been shown in other ER-positive cell lines, that is, E(2) and ICI 182,780 caused ER downregulation, whereas OH-Tam induced ER accumulation. Ligand-induced downregulation of ER involved degradation in proteasomes, since it was suppressed by the proteasome inhibitor MG-132. Exposure of IBEP-2 cells to E(2) resulted in a marked (at least 25-fold) induction of PgR, documented by EIA, immunoblotting and immunofluorescence. PgR induction due to E(2) was not modified by MG-132. Interestingly, MG-132 alone produced an ER-independent increase of PgR expression. IBEP-2 might prove to be valuable to study ER-mediated induction of PgR.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

doi

10.1023/B:BREA.0000032922.87541.31

subject

Has Abstract

pub_date

2004-07-01 00:00:00

pages

39-53

issue

1

eissn

0167-6806

issn

1573-7217

pii

5268576

journal_volume

86

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

    abstract：:NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women with HER2-positive DCIS treated by lumpectomy. The primary aim is to determine if trastuzu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-013-2755-z

    authors： Siziopikou KP,Anderson SJ,Cobleigh MA,Julian TB,Arthur DW,Zheng P,Mamounas EP,Pajon ER,Behrens RJ,Eakle JF,Leasure NC,Atkins JN,Polikoff JA,Seay TE,McCaskill-Stevens WJ,Rabinovitch R,Costantino JP,Wolmark N

    更新日期：2013-11-01 00:00:00

  • Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.

    abstract：PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9558-z

    authors： Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

    更新日期：2008-02-01 00:00:00

  • Recurrence and survival rates in British and Japanese women with breast cancer.

    abstract：:The biology of breast cancer in Japan appears to be changing in that, while post-menopausal Japanese patients have a better prognosis than comparable British women, no differences in recurrence or survival rates can now be found in pre-menopausal patients. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF02633545

    authors： Allen DS,Bulbrook RD,Chaudary MA,Hayward JL,Yoshida M,Miura S,Murai JT

    更新日期：1991-05-01 00:00:00

  • Management of brain metastases in breast cancer: a review of current practices and emerging treatments.

    abstract：PURPOSE:Breast cancer brain metastases (BCBM) are becoming an increasingly common diagnosis due to improved systemic control and more routine surveillance imaging. Treatment continues to require a multidisciplinary approach managing systemic and intracranial disease burden. Although, improvements have been made in the ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-05552-2

    authors： Mills MN,Figura NB,Arrington JA,Yu HM,Etame AB,Vogelbaum MA,Soliman H,Czerniecki BJ,Forsyth PA,Han HS,Ahmed KA

    更新日期：2020-04-01 00:00:00

  • Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors.

    abstract：:Treatment decisions in oncology are based on a balance between the efficacy of therapy and its side effects. Patients with metastases and patients with a limited prognosis are a particular challenge, since communication about the disease situation and the expected therapeutic benefit is difficult not only for patients...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2557-3

    authors： Lux MP,Bayer CM,Loehberg CR,Fasching PA,Schrauder MG,Bani MR,Häberle L,Engel A,Heusinger K,Tänzer T,Radosavac D,Scharl A,Bauerfeind I,Gesslein J,Schulte H,Overbeck-Schulte B,Beckmann MW,Hein A

    更新日期：2013-06-01 00:00:00

  • A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance.

    abstract：:A risk prediction model is a statistical tool for estimating the probability that a currently healthy individual with specific risk factors will develop a condition in the future such as breast cancer. Reliably accurate prediction models can inform future disease burdens, health policies and individual decisions. Brea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-011-1818-2

    authors： Meads C,Ahmed I,Riley RD

    更新日期：2012-04-01 00:00:00

  • Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins.

    abstract：:The complexity of breast cancer biology makes it challenging to analyze large datasets of clinicopathologic and molecular attributes, toward identifying the key prognostic features and producing systems capable of predicting which patients are likely to relapse. We applied machine-learning techniques to analyze a set ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0557-0

    authors： Asgarian N,Hu X,Aktary Z,Chapman KA,Lam L,Chibbar R,Mackey J,Greiner R,Pasdar M

    更新日期：2010-06-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract：:A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1023081624133

    authors： Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期：2003-04-01 00:00:00

  • Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?

    abstract：PURPOSE:The utilization of staging preoperative breast MRI in biopsy-proven cancer patients varies based on institution and individual clinicians. It is unclear whether primary breast cancer subtype influences a clinician's decision to obtain a preoperative breast MRI based on likelihood of multicentric or contralatera...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4426-y

    authors： Jonna AR,Sam KQ,Ebuoma LO,Sedgwick EL,Wang T,Benveniste AP

    更新日期：2017-11-01 00:00:00

  • Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

    abstract：PURPOSE:Estrogen exposure is involved in both breast cancer susceptibility and the prognosis in patients with breast cancer. Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis. The aim of this study was to examine the effect of single nucleotide pol...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9822-2

    authors： Fasching PA,Loehberg CR,Strissel PL,Lux MP,Bani MR,Schrauder M,Geiler S,Ringleff K,Oeser S,Weihbrecht S,Schulz-Wendtland R,Hartmann A,Beckmann MW,Strick R

    更新日期：2008-11-01 00:00:00

  • No evidence of human papillomavirus DNA sequences in invasive breast carcinoma.

    abstract：:Breast cancer is one of the most frequently diagnosed cancers in women in France, but its aetiology remains unknown. Viruses including Epstein-Barr virus (EBV), a human equivalent of murine mammary tumour virus (MMTV) and human papillomavirus (HPV) have been detected in benign breast tissues and breast tumours and are...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9626-4

    authors： de Cremoux P,Thioux M,Lebigot I,Sigal-Zafrani B,Salmon R,Sastre-Garau X,Institut Curie Breast Group.

    更新日期：2008-05-01 00:00:00

  • The pathology of breast cancer in Japanese women compared to other ethnic groups: a review.

    abstract：:Review of comparative pathology studies of breast cancer among Japanese women and other ethnic groups reveals consistent differences in tumor morphology and host response. Japanese women show lower rates of breast cancer than Caucasian women, a difference that is accounted for by increased rates of this cancer in post...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF02633531

    authors： Stemmermann GN

    更新日期：1991-05-01 00:00:00

  • Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.

    abstract：PURPOSE:Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating a broader range of risk factors. METHODS:Between 2009 and 2015, we conducted a case-control study of IBC at six cente...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05864-3

    authors： Schairer C,Hablas A,Eldein IAS,Gaafar R,Rais H,Mezlini A,Ayed FB,Ayoub WB,Benider A,Tahri A,Khouchani M,Aboulazm D,Karkouri M,Eissa S,Bastawisy AE,Yehia M,Gadalla SM,Swain SM,Merajver SD,Brown LM,Pfeiffer RM,Sol

    更新日期：2020-11-01 00:00:00

  • Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.

    abstract：:A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-009-0360-y

    authors： Maiorano E,Regan MM,Viale G,Mastropasqua MG,Colleoni M,Castiglione-Gertsch M,Price KN,Gelber RD,Goldhirsch A,Coates AS

    更新日期：2010-05-01 00:00:00

  • A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

    abstract：PURPOSE:Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. R...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-020-05626-1

    authors： Watanabe J,Saito M,Horimoto Y,Nakamoto S

    更新日期：2020-05-01 00:00:00

  • High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

    abstract：:Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients receiving lapatinib and capecitabine Patients received lapatinib 1,250 mg once daily and capecitabine 2,000 ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-010-1200-9

    authors： Rhee J,Han SW,Cha Y,Ham HS,Kim HP,Oh DY,Im SA,Park JW,Ro J,Lee KS,Park IH,Im YH,Bang YJ,Kim TY

    更新日期：2011-01-01 00:00:00

  • Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

    abstract：:Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry (ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this study was to disclose the prognostic significance of different morphological categories of ICC-positive cells according to treatment status an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2439-8

    authors： Synnestvedt M,Borgen E,Schlichting E,Schirmer CB,Renolen A,Giercksky KE,Nesland JM,Naume B

    更新日期：2013-04-01 00:00:00

  • A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.

    abstract：PURPOSE:Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated cardiac events in patients with HER2-positive early breast cancer (EBC) treated with H IV as adjuvant therapy in routine practice. METHODS:The observatio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-5058-6

    authors： Lidbrink E,Chmielowska E,Otremba B,Bouhlel A,Lauer S,Liste Hermoso M,Nüesch E,Shing M,Misra V

    更新日期：2019-02-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract：PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4749-3

    authors： Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期：2018-07-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract：:The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0080-8

    authors： Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期：2009-05-01 00:00:00

  • Meta-analysis to determine the clinical impact of axillary lymph node dissection in the treatment of invasive breast cancer.

    abstract：:There are divergent opinions regarding the optimum surgical management of the axilla in patients with invasive breast cancer. Guidelines mandate axillary lymph node dissection (ALND) in the setting of positive sentinel lymph nodes. However, recent studies have questioned the true benefits of this procedure. Therefore,...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-015-3549-2

    authors： Joyce DP,Manning A,Carter M,Hill AD,Kell MR,Barry M

    更新日期：2015-09-01 00:00:00

  • Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

    abstract：:This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-004-4384-z

    authors： Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

    更新日期：2004-11-01 00:00:00

  • Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.

    abstract：:The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip, Roche that facilitates the classification of individuals by testing 27...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0328-y

    authors： Ramón y Cajal T,Altés A,Paré L,del Rio E,Alonso C,Barnadas A,Baiget M

    更新日期：2010-01-01 00:00:00

  • Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer.

    abstract：:Mastopathy is a common disease of the breast likely associated with elevated estrogen levels and a putative risk factor for breast cancer. The role of estrogen receptor alpha (ESR1) in mastopathy has not been investigated previously. Here, we investigated the prevalence of ESR1 gene amplification in mastopathy and its...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3427-y

    authors： Soysal SD,Kilic IB,Regenbrecht CR,Schneider S,Muenst S,Kilic N,Güth U,Dietel M,Terracciano LM,Kilic E

    更新日期：2015-06-01 00:00:00

  • Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

    abstract：:The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 19...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1712-y

    authors： Cho YH,Shen J,Gammon MD,Zhang YJ,Wang Q,Gonzalez K,Xu X,Bradshaw PT,Teitelbaum SL,Garbowski G,Hibshoosh H,Neugut AI,Chen J,Santella RM

    更新日期：2012-01-01 00:00:00

  • Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.

    abstract：PURPOSE:In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1-T2 cN0 early breast cancer and 1-2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3-...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05876-z

    authors： Riedel F,Heil J,Feisst M,Moderow M,von Au A,Domschke C,Michel L,Schaefgen B,Golatta M,Hennigs A

    更新日期：2020-11-01 00:00:00

  • Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

    abstract：PURPOSE:When combined with anthracyclines, the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) provides significant clinical benefit for women with HER2-overexpressing metastatic breast cancer. However, its use is limited by severe cardiotoxicity. To clarify whether myocardial HER2 and HER4 expression i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/b:brea.0000003916.39959.73

    authors： Fuchs IB,Landt S,Bueler H,Kuehl U,Coupland S,Kleine-Tebbe A,Lichtenegger W,Schaller G

    更新日期：2003-11-01 00:00:00

  • Tai chi for breast cancer patients: a systematic review.

    abstract：:The objective of this review was to assess the effectiveness of tai chi for supportive breast cancer care. Eleven databases were searched from inception through December 2009. Controlled trials testing tai chi in patients with breast cancer that assessed clinical outcome measures were considered. The selection of stud...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-010-0741-2

    authors： Lee MS,Choi TY,Ernst E

    更新日期：2010-04-01 00:00:00

  • Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

    abstract：:Tamoxifen is currently the adjuvant treatment of choice for postmenopausal women with hormone-sensitive breast cancer. However, in the treatment of postmenopausal women with advanced disease, the third-generation aromatase inhibitor anastrozole ('Arimidex') has been shown to be at least as effective as tamoxifen, and ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1025455130476

    authors： Aapro MS,Forbes JF

    更新日期：2003-01-01 00:00:00

  • Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium.

    abstract：:Digital breast tomosynthesis (DBT) is emerging as the new standard of care for breast cancer screening based on improved cancer detection coupled with reductions in recall compared to screening with digital mammography (DM) alone. However, many prior studies lack follow-up data to assess false negatives examinations. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3695-1

    authors： Conant EF,Beaber EF,Sprague BL,Herschorn SD,Weaver DL,Onega T,Tosteson AN,McCarthy AM,Poplack SP,Haas JS,Armstrong K,Schnall MD,Barlow WE

    更新日期：2016-02-01 00:00:00